No clear differences were found for overall and tumor-specific survival, while the rate of CD8+ apoptotic cells after the combined treatment of 2 Gy and Oxaliplatin still shows a tendency (p = 0.089) to increase tumor-specific survival (data not shown). Here, CD8A is linked to neoplasm.